Am J Psychiatry 158:1067-1074, July 2001
© 2001 American Psychiatric Association
A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Larry Scahill, M.S.N., Ph.D.,
Phillip B. Chappell, M.D.,
Young S. Kim, M.D.,
Robert T. Schultz, Ph.D.,
Lily Katsovich, M.S.,
Elizabeth Shepherd, M.A.,
Amy F.T. Arnsten, Ph.D.,
Donald J. Cohen, M.D., and
James F. Leckman, M.D.
OBJECTIVE: This study evaluated the efficacy and safety of guanfacine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). METHOD: Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with guanfacine or placebo under double-blind conditions. Follow-up visits occurred every 2 weeks for safety monitoring and dose adjustment. RESULTS: Thirty-four medication-free subjects (31 boys and three girls with a mean age of 10.4 years) with ADHD, combined type, and a tic disorder participated. After 8 weeks of treatment, guanfacine was associated with a mean improvement of 37% in the total score on the teacher-rated ADHD Rating Scale, compared to 8% improvement for placebo. Nine of 17 subjects who received guanfacine were blindly rated on the Clinical Global Improvement scale as either much improved or very much improved, compared with none of 17 subjects who received placebo. The mean score on the parent-rated hyperactivity index improved by 27% in the guanfacine group and 21% in the placebo group, not a significant difference. On the Continuous Performance Test, commission errors decreased by 22% and omission errors by 17% in the guanfacine group, compared with increases of 29% in commission errors and of 31% in omission errors in the placebo group. Tic severity decreased by 31% in the guanfacine group, compared to 0% in the placebo group. One guanfacine subject with sedation withdrew at week 4. Guanfacine was associated with insignificant decreases in blood pressure and pulse. CONCLUSIONS: Guanfacine appears to be a safe and effective treatment for children with tic disorders and ADHD.
This article has been cited by other articles:
|
|
|
|
 
R. J. Hagerman, E. Berry-Kravis, W. E. Kaufmann, M. Y. Ono, N. Tartaglia, A. Lachiewicz, R. Kronk, C. Delahunty, D. Hessl, J. Visootsak, et al.
Advances in the Treatment of Fragile X Syndrome
Pediatrics,
January 1, 2009;
123(1):
378 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Focus,
July 1, 2008;
6(3):
401 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Circulation,
May 6, 2008;
117(18):
2407 - 2423.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Spencer, F. R. Sallee, D. L. Gilbert, D. W. Dunn, J. T. McCracken, B. J. Coffey, C. L. Budman, R. K. Ricardi, H. L. Leonard, A. J. Allen, et al.
Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
J Atten Disord,
January 1, 2008;
11(4):
470 - 481.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Biederman, R. D. Melmed, A. Patel, K. McBurnett, J. Konow, A. Lyne, N. Scherer, and for the SPD503 Study Group
A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Pediatrics,
January 1, 2008;
121(1):
e73 - e84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. T. Arnsten
Catecholamine and Second Messenger Influences on Prefrontal Cortical Networks of "Representational Knowledge": A Rational Bridge between Genetics and the Symptoms of Mental Illness
Cereb Cortex,
September 1, 2007;
17(suppl_1):
i6 - i15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. T. Brady and R. Sinha
Co-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic Stress
Focus,
January 1, 2007;
5(2):
229 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Ramos, D. Stark, L. Verduzco, C. H. van Dyck, and A. F.T. Arnsten
{alpha}2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals
Learn. Mem.,
November 1, 2006;
13(6):
770 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P Gibson, T. L Bettinger, N. C Patel, and M L. Crismon
Atomoxetine Versus Stimulants for Treatment of Attention Deficit/Hyperactivity Disorder
Ann. Pharmacother.,
June 1, 2006;
40(6):
1134 - 1142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sinha, M. Garcia, P. Paliwal, M. J. Kreek, and B. J. Rounsaville
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes.
Arch Gen Psychiatry,
March 1, 2006;
63(3):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Allen, R. M. Kurlan, D. L. Gilbert, B. J. Coffey, S. L. Linder, D. W. Lewis, P. K. Winner, D. W. Dunn, L. S. Dure, F. R. Sallee, et al.
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Neurology,
December 27, 2005;
65(12):
1941 - 1949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Piacentini and S. Chang
Habit Reversal Training for Tic Disorders in Children and Adolescents
Behav Modif,
November 1, 2005;
29(6):
803 - 822.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. T. Brady and R. Sinha
Co-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic Stress
Am J Psychiatry,
August 1, 2005;
162(8):
1483 - 1493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Yuan, Z. Wu, I. A. Kostenyuk, and J. K. Burns
G-protein-coupled {alpha}2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase
J. Exp. Bot.,
July 1, 2005;
56(417):
1867 - 1875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Wolraich, C. J. Wibbelsman, T. E. Brown, S. W. Evans, E. M. Gotlieb, J. R. Knight, E. C. Ross, H. H. Shubiner, E. H. Wender, and T. Wilens
Attention-Deficit/Hyperactivity Disorder Among Adolescents: A Review of the Diagnosis, Treatment, and Clinical Implications
Pediatrics,
June 1, 2005;
115(6):
1734 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Riba, A. Rodriguez-Fornells, A. Morte, T. F. Munte, and M. J. Barbanoj
Noradrenergic Stimulation Enhances Human Action Monitoring
J. Neurosci.,
April 27, 2005;
25(17):
4370 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Bailey
An Exceptional Case of Plagiarism!
J Psychopharmacol,
September 1, 2004;
18(3):
291 - 292.
[PDF]
|
|
|
|
|
|
|
D. M. Shin, S. Korada, R. Raballo, C. S. Shashikant, A. Simeone, J. R. Taylor, and F. Vaccarino
Loss of Glutamatergic Pyramidal Neurons in Frontal and Temporal Cortex Resulting from Attenuation of FGFR1 Signaling Is Associated with Spontaneous Hyperactivity in Mice
J. Neurosci.,
March 3, 2004;
24(9):
2247 - 2258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Austin
Pharmacological Interventions for Students with ADD
Intervention in School and Clinic,
May 1, 2003;
38(5):
289 - 296.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. J. Safer, J. M. Zito, and S. dosReis
Concomitant Psychotropic Medication for Youths
Am J Psychiatry,
March 1, 2003;
160(3):
438 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Connor, R. T. Boone, R. J. Steingard, I. D. Lopez, and R. H. Melloni JR
Psychopharmacology and Aggression: II. A Meta-Analysis of Nonstimulant Medication Effects on Overt Aggression-Related Behaviors in Youth with SED
Journal of Emotional and Behavioral Disorders,
January 1, 2003;
11(3):
157 - 168.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S. Franowicz, L. E. Kessler, C. M. D. Borja, B. K. Kobilka, L. E. Limbird, and A. F. T. Arnsten
Mutation of the alpha 2A-Adrenoceptor Impairs Working Memory Performance and Annuls Cognitive Enhancement by Guanfacine
J. Neurosci.,
October 1, 2002;
22(19):
8771 - 8777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Tan, M. H. Wilson, L. B. MacMillan, B. K. Kobilka, and L. E. Limbird
Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists
PNAS,
September 17, 2002;
99(19):
12471 - 12476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kuczenski and D. S. Segal
Exposure of Adolescent Rats to Oral Methylphenidate: Preferential Effects on Extracellular Norepinephrine and Absence of Sensitization and Cross-Sensitization to Methamphetamine
J. Neurosci.,
August 15, 2002;
22(16):
7264 - 7271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Spencer, J. Biederman, B. Coffey, D. Geller, M. Crawford, S. K. Bearman, R. Tarazi, and S. V. Faraone
A Double-blind Comparison of Desipramine and Placebo in Children and Adolescents With Chronic Tic Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder
Arch Gen Psychiatry,
July 1, 2002;
59(7):
649 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nass and S. Bressman
Attention deficit hyperactivity disorder and Tourette syndrome: What's the best treatment?
Neurology,
February 26, 2002;
58(4):
513 - 514.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Treatment of ADHD in children with tics: A randomized controlled trial
Neurology,
February 26, 2002;
58(4):
527 - 536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guanfacine Effective for Comorbid Tic Disorder and ADHD
Journal Watch Psychiatry,
July 26, 2001;
2001(726):
9 - 9.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
